Posted by Michael Wonder on 06 Nov 2020
Brilinta approved in the US to reduce the risk of stroke in patients with an acute ischaemic stroke or high-risk transient ischaemic attack
6 November 2020 - New indication expands use of Brilinta beyond cardiovascular disease to patients with mild-to-moderate stroke
AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischaemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischaemic attack.
The approval by the US FDA was based on positive results from the THALES Phase 3 trial that showed aspirin plus Brilinta 90 mg significantly reduced the rate of the composite of stroke and death compared to aspirin alone in patients with acute ischaemic stroke or transient ischaemic attack.
